Mr. Chet Burrell, former president and CEO of Care First Blue Cross Blue Shield and Executive Chairman of the Intervention Insights Board of Directors, discusses the challenges payers face in managing the growth of precision medicine for cancer care and why he's championing Trapelo's precision diagnostic platform as the first collaborative technology solution.

In this first episode with Dr. Jack West, we discuss the state of precision oncology and the challenges providers face when it comes to performing the right molecular tests to appropriately prescribe targeted therapies. Leave a review and subscribe here.

In this first episode with Dr. Jack West, we discuss the state of precision oncologyand the challenges providers face when it comes to performing the right molecular tests to appropriately prescribe targeted therapies. Leave a review and subscribe here.

Laboratories could be considered the epicenter of the precision medicine industry, so we were thrilled to have Dr. Michael Astion, Medical Director for the Department of Laboratories at Seattle Children's Hospital join us. In this episode, he introduces us to PLUGS, (Patient Centered Laboratory Utilization Guidance Service) a grassroots program he co-founded that exists to promote and strengthen laboratory stewardship.

We’ve received many questions about the challenges clinicians face in knowing when to use pharmacogenetic tests in practice. So we invited our resident "genome educator" back! Inthis episodeJeanette McCarthy, co-founder of Precision Medicine Advisors, returns to address those questions and discuss some of the issues health care providers face. Listen here.

Dr. Michael Kolodziej is Vice President and Chief Innovation Officer at ADVI Health, a Washington, D.C.-based healthcare consulting and strategy firm, and a pioneer in developing value-based reimbursement models for cancer care. Having seen him present his talk, “The Healthcare Landscape of 2025: 3 Trends That Can Change Cancer Care Forever,” at a Florida Association of Clinical Oncology (FLASCO) event, we were anxious to revisit his thinking on the subject.

In this podcast, we start with the first of the three trends Dr. Kolodziej mentions in his talk: Biosimilars. We asked Dr. Kolodziej to explain what biosimilars are and how they are impacting the cost of cancer care today.

Dr. Windy Dean-Colomb, an MD Anderson-trained MD, PhD, and practicing medical oncologist, and Dr. Clayton Yates, a professor of biology at Tuskegee University and director of the university's Multidisciplinary Center for Biomedical Research, join us to discuss the importance of studying and addressing racial disparities in oncology.

How precision medicine is moving oncologists away from population-based treatments to more patient-appropriate care.

Dr. Lee Newcomer, board-certified oncologist and former SVP of oncology and genetics at UnitedHealthcare, answers pressing questions about the current costs of cancer care, how diagnostics are currently reimbursed and who should control the development of those diagnostics. His answers gave us a lot to think about.

Precision Medicine Podcast guest Dr. Sandeep “Bobby” Reddy talks about how he became an early adopter of precision medicine and the opportunities that exist to present its economic benefits. Listen to the full episode here.

In epsiode 6, Dr. Peter Beitsch, Chief Physician of the Dallas Surgical Group and an executive with the TME Breast Cancer Network, joined us to discuss his study published by the Clinical Journal of Oncology titled, Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? During the episode, he spoke in-depth about the results of that study and the implications for the future of precision medicine in cancer care.

This episode is Part Two of that discussion in which we learn more about how Dr. Beitsch uncovered flaws in population-based cancer treatments and began to advocate for individualized patient care.